Neurocrine Biosciences Inc. and Sosei Group Corporation have signed a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.
I don’t know much about “novel muscarinic receptor agonists”. But at least they’re still trying to develop new meds.
Muscarinic receptor effect to schizo had been identified in 1970s its old science with new technology to combat its side effect, taar1 is more recent in 2001 iirc